How could the intense competition between Amgen and Gilead affect Eli Lilly and Company?
Increased biotech rivalry may intensify competitive pressure on Eli Lilly's market share The intense competition between major players like Amgen and Gilead Sciences drives the overall competitive dynamics within the global pharmaceutical market. Since the reports note that Gilead Sciences and Eli Lilly and Company actively compete against each other, the heightened rivalry in the sector increases the pressure on Eli Lilly. This pressure stems from the aggressive strategies and product growth demonstrated by competitors, such as Amgen's 9% year-over-year product sales increase and its pipeline of 17 drugs on track to be blockbusters.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Over the long term
- The story
- No new developments lately
How it reaches Eli Lilly and Company
-
A comparison of Amgen and Gilead Sciences noted that both companies offer attractive dividends within the biotech sector. Amgen has a forward dividend yield exceeding 2.2%, while Gilead Sciences' yield is slightly below 2.1%. Gilead Sciences reported a dividend payout ratio of 43.5%, compared to Amgen's 60.9%, and trades at a forward earnings multiple of 15.6 times versus Amgen's 16.7 times.
The full event1independent outlet -
The competitive dynamics established between Gilead Sciences and other major players influence the broader pharmaceutical market. The reports explicitly state that Gilead Sciences and Eli Lilly and Company actively compete against each other in the global pharmaceutical market.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American pharmaceutical company
Everything about Eli Lilly and Company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Amgen's product sales increased by 9% year over year in its latest quarter, compared to 8% growth for Gilead Sciences.fool.com
- Amgen has 17 drugs on track to be blockbusters this year versus eight for Gilead Sciences.fool.com
- Gilead Sciences and Eli Lilly and Company actively compete against each other in the global pharmaceutical market.fool.com
Why it matters
For Eli Lilly and Company, operating in a highly competitive global pharmaceutical market means that the performance and strategic moves of rivals like Amgen and Gilead directly influence its market position and revenue streams. The increased intensity of competition, driven by aggressive product growth and large pipelines from peers, necessitates continuous innovation and strategic investment to maintain market share.
This rivalry is characteristic of the modern biotech industry, where companies like Amgen and Gilead are noted exceptions to the rule of small, non-dividend-paying biotech firms. The reports highlight that investors must research the current product lineups and competitive dynamics to assess a company's ability to continue paying dividends, underscoring the high stakes of competitive positioning in the sector.
What we don't know yet
- How will Eli Lilly adjust its R&D strategy in response to the pipeline strength of Amgen and Gilead?
- Will the competitive pressure lead to changes in pricing or market access for Eli Lilly's key products?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- fool.comSunday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.